The crystal study:: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri

被引：0
|
作者：
Van Cutsem, E. [1 ]
Lang, I [2 ]
D'haens, G. [3 ]
Moiseyenko, V [4 ]
Zaluski, J. [5 ]
Koehne, C. [6 ]
Folprecht, G. [7 ]
Tejpar, S. [1 ]
Shparyk, Y. [8 ]
Schlichting, M. [9 ]
Kisker, O. [9 ]
Stroh, C. [9 ]
Rougier, P. [10 ]
机构：
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] Orszagos Onkol Intezet, Budapest, Hungary
[3] Imelda Ziekenhuis, Bonheiden, Belgium
[4] NN Petrov Oncol Res Inst, St Petersburg, Russia
[5] Weikopolskie Centrum Onkol, Poznan, Poland
[6] Klinikum Oldenburg, Oldenburg, Germany
[7] Univ Klin Carl Gustav Carus, Dresden, Germany
[8] Lviv Oncol Med & Diagnost Ctr, Lvov, Ukraine
[9] Merck Serono, Darmstadt, Germany
[10] Hop Ambroise Pare, Boulogne, France
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [31] Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.
    Ciardiello, Fortunato
    Lenz, Heinz-Josef
    Kohne, Claus-Henning
    Heinemann, Volker
    Tejpar, Sabine
    Melezinek, Ivan
    Beier, Frank
    Stroh, Christopher
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] EGFR gene copy number and clinical outcome to cetuximab plus FOLFIRI regimen (folcetux) in first-line treatment of metastatic and locally advanced gastric cancer
    Cerea, Giulio
    Sartore-Bianchi, Andrea
    Veronese, Silvio
    Andreotti, Ines Chiara
    Di Fabio, Francesca
    Funaioli, Chiara
    Llimpe, Fabiola Lorena Rojas
    Martoni, Andrea Angelo
    Pinto, Carmine
    Siena, Salvatore
    ANNALS OF ONCOLOGY, 2006, 17 : 250 - 250
  • [33] Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC).
    Moosmann, N.
    von Weikersthal, L. Fischer
    Vehling-Kaiser, U.
    Stauch, M.
    Dietzfelbinger, H. F.
    Oruzio, D. V.
    Klein, S.
    Stintzing, S.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
    Stintzing, S.
    von Weikersthal, L. Fischer
    Decker, T.
    Vehling-Kaiser, U.
    Jaeger, E.
    Heintges, T.
    Stoll, C.
    Giessen, C.
    Modest, D. P.
    Neumann, J.
    Jung, A.
    Kirchner, T.
    Scheithauer, W.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2012, 23 (07) : 1693 - 1699
  • [35] Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES study).
    Normanno, Nicola
    Rachiglio, Anna Maria
    Abate, Riziero Esposito
    Orlandi, Armando
    Maiello, Evaristo
    Maglietta, Giuseppe
    Damato, Angela
    Maiello, Monica Rosaria
    Carotenuto, Marianeve
    Calegari, Maria Alessandra
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria Giulia
    Tamberi, Stefano
    Lonardi, Sara
    Avallone, Antonio
    Latiano, Tiziana Pia
    Tamburini, Emiliano
    Barone, Carlo Antonio
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] The role of the KRAS G13D mutation in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy plus cetuximab
    Tejpar, S.
    Bokemeyer, C.
    Celik, I.
    Schlichting, M.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [37] Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: Effect of KRAS mutation on treatment efficacy in Taiwanese patients
    Chen, M. C.
    Chiang, F. F.
    Wang, H. M.
    NEOPLASMA, 2013, 60 (05) : 561 - 567
  • [38] SURVIVAL ACCORDING TO PROGNOSTIC RISK FACTORS IN PATIENTS RECEIVING FIRST-LINE CHEMOTHERAPY PLUS CETUXIMAB IN THE CRYSTAL AND OPUS STUDIES
    Koehne, Claus-Henning
    Van Cutsem, Eric
    Bokemeyer, Carsten
    Schlichting, Michael
    Heeger, Steffen
    Folprecht, Gunnar
    ANNALS OF ONCOLOGY, 2012, 23 : 11 - 11
  • [39] ECONOMIC EVALUATION OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) BASED ON IRINOTECAN (FOLFIRI) plus BEVACIZUMAB OR CETUXIMAB, ADJUSTED BY KRAS GENE (WILD-TYPE (WT) OR MUTANT (MT))
    Torrecillas, L.
    Vargas, J.
    VALUE IN HEALTH, 2008, 11 (06) : A469 - A470
  • [40] The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study
    Tsai, Hsiang-Lin
    Lin, Chun-Chi
    Sung, Yung-Chung
    Chen, Shang-Hung
    Chen, Li-Tzong
    Jiang, Jeng-Kai
    Wang, Jaw-Yuan
    BRITISH JOURNAL OF CANCER, 2023, 129 (06) : 947 - 955
12345